SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
     
SCHEDULE 13G/A
     
Under the Securities Exchange Act of 1934
 
(Amendment No.  1)*
 

Clovis Oncology, Inc.

(Name of Issuer)
 

Common Stock, par value $0.001 per share

(Title of Class of Securities)
 

189464100

(CUSIP Number)
 

December 31, 2019

(Date of event which requires filing of this statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
 
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
 
(Page 1 of 7 Pages)

 

______________________________

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

CUSIP No. 189464100 13G/A Page 2 of 7 Pages

 

1

NAMES OF REPORTING PERSONS

Highbridge Capital Management, LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

State of Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

4,554,068 shares of Common Stock (including 4,454,068 shares of Common Stock issuable upon conversion of convertible notes and 100,000 shares of Common Stock issuable upon exercise of call options)

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

4,554,068 shares of Common Stock (including 4,454,068 shares of Common Stock issuable upon conversion of convertible notes and 100,000 shares of Common Stock issuable upon exercise of call options)

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,554,068 shares of Common Stock (including 4,454,068 shares of Common Stock issuable upon conversion of convertible notes and 100,000 shares of Common Stock issuable upon exercise of call options)

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

7.68%

12

TYPE OF REPORTING PERSON

IA, OO

         

 

 

 

CUSIP No. 189464100 13G/A Page 3 of 7 Pages

 

1

NAMES OF REPORTING PERSONS

Highbridge Tactical Credit Master Fund, L.P. (formerly known as 1992 Tactical Credit Master Fund, L.P.)

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

State of Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

4,554,068 shares of Common Stock (including 4,454,068 shares of Common Stock issuable upon conversion of convertible notes and 100,000 shares of Common Stock issuable upon exercise of call options)

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

4,554,068 shares of Common Stock (including 4,454,068 shares of Common Stock issuable upon conversion of convertible notes and 100,000 shares of Common Stock issuable upon exercise of call options)

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,554,068 shares of Common Stock (including 4,454,068 shares of Common Stock issuable upon conversion of convertible notes and 100,000 shares of Common Stock issuable upon exercise of call options)

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

7.68%

12

TYPE OF REPORTING PERSON

PN

         

 

 

 

 

CUSIP No. 189464100 13G/A Page 4 of 7 Pages

 

Item 1(a). NAME OF ISSUER:
   
  The name of the issuer is Clovis Oncology, Inc. (the "Company").

 

Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
   
  The Company's principal executive offices are located at 5500 Flatiron Parkway, Suite 100, Boulder, Colorado 80301.

 

Item 2(a). NAME OF PERSON FILING:
Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Item 2(c). CITIZENSHIP:

 

  This statement is filed by:
   
  (i)

Highbridge Capital Management, LLC

277 Park Avenue, 23rd Floor

New York, New York 10172

Citizenship: State of Delaware

   
  (ii)

Highbridge Tactical Credit Master Fund, L.P. (formerly known as 1992 Tactical Credit Master Fund, L.P.)

277 Park Avenue, 23rd Floor

New York, New York 10172

Citizenship: State of Delaware

   
  The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."  

 

Item 2(d). TITLE OF CLASS OF SECURITIES:
   
  Common Stock, par value $0.001 per share (the "Common Stock").

 

Item 2(e). CUSIP NUMBER:
   
  189464100

 

Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

 

  (a) ¨ Broker or dealer registered under Section 15 of the Act,
  (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
  (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
  (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,

 

 

 

CUSIP No. 189464100 13G/A Page 5 of 7 Pages

 

  (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
  (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
  (g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
  (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
  (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
  (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
  (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

 

 

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

specify the type of institution:___________________________________

 

Item 4. OWNERSHIP.
   
  (a) Amount beneficially owned:
   
  As of December 31, 2019, (i) Highbridge Capital Management, LLC, as the trading manager of Highbridge Tactical Credit Master Fund, L.P., may be deemed to be the beneficial owner of the 4,554,068 shares of Common Stock (including 4,454,068 shares of Common Stock issuable upon conversion of convertible notes and 100,000 shares of Common Stock issuable upon exercise of call options) held by Highbridge Tactical Credit Master Fund, L.P. and (ii) Highbridge Tactical Credit Master Fund, L.P. may be deemed to be the beneficial owner of the 4,554,068 shares of Common Stock (including 4,454,068 shares of Common Stock issuable upon conversion of convertible notes and 100,000 shares of Common Stock issuable upon exercise of call options) held by it.
   
  (b) Percent of class:
   
  The percentages used herein and in the rest of this Schedule 13G/A are calculated based upon 54,815,202 shares of Common Stock reported to be outstanding as of November 1, 2019, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019 filed with the Securities and Exchange Commission on November 7 2019, and assumes the conversion of the convertible notes reported herein.  Therefore, as of December 31, 2019, (i) Highbridge Capital Management, LLC may be deemed to beneficially own approximately 7.68% of the outstanding shares of Common Stock and (ii) Highbridge Tactical Credit Master Fund, L.P. may be deemed to beneficially own approximately 7.68% of the outstanding shares of Common Stock.
   
  The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the shares of Common Stock issuable upon conversion of the convertible notes and exercise of the call options held by Highbridge Tactical Credit Master Fund, L.P.

 

 

 

CUSIP No. 189464100 13G/A Page 6 of 7 Pages

 

  (c) Number of shares as to which such person has:
   
  (i)     Sole power to vote or to direct the vote
   
  0
   
  (ii)    Shared power to vote or to direct the vote
   
  See Item 4(a)
   
  (iii)   Sole power to dispose or to direct the disposition of
   
  0
   
  (iv)   Shared power to dispose or to direct the disposition of
   
  See Item 4(a)

 

Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
   
  Not applicable.

 

Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
   
  Not applicable.

 

Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
   
  Not applicable.

 

Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
   
  Not applicable.

 

Item 9. NOTICE OF DISSOLUTION OF GROUP.
   
  Not applicable.

 

Item 10. CERTIFICATION.

 

  Each Reporting Person hereby makes the following certification:
   
  By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

CUSIP No. 189464100 13G/A Page 7 of 7 Pages

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

DATED: February 13, 2020

 

HIGHBRIDGE CAPITAL MANAGEMENT, LLC
     
     
By: /s/ John Oliva  
Name: John Oliva  
Title: Managing Director  
     
     
HIGHBRIDGE TACTICAL CREDIT MASTER FUND, L.P.
     
     
By:

Highbridge Capital Management, LLC

its Trading Manager

     
     
By: /s/ John Oliva  
Name: John Oliva  
Title: Managing Director  

 

Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Clovis Oncology Charts.
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Clovis Oncology Charts.